| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC3508 |
| Trial ID | NCT05943990 |
| Disease | Myxoid Liposarcoma | Synovial Sarcoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | GSK3901961 |
| HLA | HLA-A*02:01|HLA-A*02:05|HLA-A*02:06 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NY ESO 1 and LAGE 1a, and Co-expressing the dnTGF-βRII (GSK3845097) in Participants With NY ESO 1 and/or LAGE 1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | GlaxoSmithKline |
| Other ID(s) | 209012 Substudy 2|2019-004446-14 |
| Cohort 1 | |||||||||
|
|||||||||